With market exclusivity for regular Eylea ending, the company has positioned its high-dose version, marketed with Bayer ...

Regeneron should weather the Eylea biosimilar launch storm and continue to deliver long-term shareholder value. See why REGN ...

With U.S. sales of $392 million in the third quarter, Regeneron’s high-dose version of Eylea is closing in on blockbuster sales in its first full year on the market. The bad news for the company, ...

Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously ...

With “nerves of steel,” Amgen is getting ready to sell a copycat of Regeneron’s top-selling eye drug Eylea, even as ...

This NMA serves to bridge the gap between trials for both therapies and compare them to one another based on existing data.

By squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. | Despite ...

U.S. drugmaker Regeneron Pharmaceuticals on Thursday reported weaker-than-expected quarterly sales of the higher dose version ...

The U.S. Court of Appeals for the Federal Circuit rejected Regeneron's request to block the launch during its appeal of a ...

Amgen's move follows the lifting of a temporary injunction on the launch of its Pavblu-branded biosimilar by the US Court of ...

Regeneron reports better-than-expected third-quarter results, beating earnings and revenue estimates, driven by strong Eylea HD, Dupixent and Libtayo sales.

Canaccord Genuity analyst John Newman has maintained their bullish stance on REGN stock, giving a Buy rating today. John Newman has given his ...